Continued recognition by industry and non-industry experts as unique partner in Orphan Drug Development
Hoofddorp, The Netherlands, November 24, 2014 / B3C Newswire / - The PSR-Agility Orphan Drug Development partnership has for the second consecutive year been awarded “Best Orphan Drug Contract Research Organisation” in the Rare & Orphan Advocacy and Research (ROAR) Awards (http://goo.gl/CUyAly).
The ROAR Awards were announced during the 5th Annual World Orphan Drug Congress Europe, November 12-14, 2014, in Brussels, Belgium. The 2014 awards recognize those who have done outstanding work in the rare disease field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of orphan drugs in the last year.
“Successively winning this award as the PSR-Agility Orphan Drug Development partnership is a clear appreciation by all stakeholders of our continued commitment in the rare disease community,” says Roger Legtenberg, CEO of PSR Orphan Experts. “Our efforts to provide crucial patient assistance by a range of services in order to lower the burden of rare disease patients in clinical trials, together with added infrastructure to be able to offer innovative patient recruitment solutions, have among others contributed considerably towards winning this award.”
“We’re thrilled that our commitment to innovating clinical development strategies for clients developing orphan drugs has been recognized consistently during our company’s first two years of partnership,” says Ellen Morgan, CEO of Agility. “Our vision for making a difference by dedicating ourselves to this specialty has become a reality.”
Orphan drugs present fundamentally different regulatory and operational challenges compared to their traditional counterparts. PSR-Agility Orphan Drug Development specializes in assisting companies to develop efficiencies and economies of scale to bring innovative new orphan products to market, thereby contributing to the IRDiRC 2020 goal to deliver 200 new therapies for rare diseases. Our staff are all highly engaged to the rare disease cause, by providing education, taking part in fundraising events and being involved in public-private partnerships. Building successful partnerships with all stakeholders, including patient organizations, industry and key opinion leaders, and actively collaborating with them, is of crucial importance.
Caption: The PSR-Agility Orphan Drug Development partnership has been awarded “Best Orphan Drug Contract Research Organisation”. From left to right: Thijs op de Weegh, Kristi Clark, Roger Legtenberg and ‘Award ceremony representative’.
About PSR-Agility Orphan Drug Development
PSR Orphan Experts and Agility Clinical partnered early 2013 in order to benefit from a unique synergy and extend the partnership’s capabilities across the Atlantic. PSR Orphan Experts was established in 1998 and has become a leading expert in orphan drug development in Europe. Agility Clinical, founded in April 2012 with an experienced executive management team, specializes in orphan drug development in North America. PSR-Agility’s mission is to help small and virtual pre-clinical and clinical stage companies design and execute successful clinical development programs for orphan indications. The partnership specializes in complex clinical development programs requiring innovative regulatory and clinical approaches. In addition to consulting (orphan drug designations, scientific advice / protocol assistance, (pre-)IND, pediatric investigation plans, NDA/MAA), the partnership provides customized full clinical trial services including project management, clinical operations, data management, biostatistics, medical, regulatory, and scientific affairs, and medical writing. PSR-Agility has a true appreciation for the challenges its clients face in obtaining the expertise they need.
Media contact:
Roger J. Legtenberg
Chief Executive Officer
PSR Orphan Experts
+31 23 556 3221
This email address is being protected from spambots. You need JavaScript enabled to view it.